Christopher E. Hart

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Wen Shen, Cheryl Li De Hoyos, Michael T. Migawa et al. · Nature Biotechnology · 2019 · 333 citations

Medicine, Biochemistry, Pharmacology +13

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts

Sebastien A. Burel, Christopher E. Hart, Patrick Cauntay et al. · Nucleic Acids Research · 2015 · 200 citations · Full text

Life Sciences, Molecular Biology, Toxicology +16

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages

Michael T. Migawa, Guillermo Vasquez, Heather Murray et al. · Nucleic Acids Research · 2014 · 129 citations · Full text

Pharmacy, Biochemistry, Chemistry +16

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

Stanley T. Crooke, Brenda F. Baker, T. Jesse Kwoh et al. · Molecular Therapy · 2016 · 113 citations · Full text

Pharmacy, Pharmacology, Toxicology +15

Dynamic and complex transcription factor binding during an inducible response in yeast

Li Ni, Can Bruce, Christopher E. Hart et al. · Genes & Development · 2009 · 108 citations · Full text

Life Sciences, Biology, Molecular Biology +15